Department of Pathology, Microbiology, and Immunology


   Oluwole Fadare, M.D.



Associate Professor

Dept. of Pathology, Microbiology and Immunology 

Dept of Obstetrics & Gynecology

Medical Director, Histopathology Laboratory

Associate Director of Surgical Pathology



  Contact Information



Office Location:


  Phone:  615.343.3793

Fax: 615.322.0511

E-mail: oluwole.fadare@vanderbilt.edu


Campus Mail address:

Pathology, Microbiology and Immunology-3rd Fl

C-3321 MCN (2561)


US Mailing address:

Dept of Pathology, Microbiology and Immunology-3rd Fl

Vanderbilt University School of Medicine

C-3321 MCN

Nashville, TN 37232-2561




Research Keywords



Pathology of Gynecologic, Obstetric, and Genitourinary Organs



Research Description



Histopathologic diagnosis, clinicopathologic features and molecular pathogenesis of gynecologic tract cancers and precancers, with an emphasis on endometrial clear cell carcinomas and uterine leiomyosarcomas



Clinical Research Description








Fadare, O, James, S, Desouki, MM, Khabele, D. Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas. Ann Diagn Pathol, 2013

Fadare, O, Gwin, K, Desouki, MM, Crispens, MA, Jones, HW, Khabele, D, Liang, SX, Zheng, W, Mohammed, K, Hecht, JL, Parkash, V. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod Pathol, 2013

Fadare, O, Khabele, D. Salpingo-oophorectomy specimens for endometrial cancer staging: a comparative analysis of representative sampling versus whole tissue processing. Hum Pathol, 44(4), 643-50, 2013

Fadare, O. Is there an association between type II endometrial carcinomas and breast cancers? A critical appraisal. Womens Health (Lond Engl), 9(4), 315-7, 2013

Fadare, O, Zheng, W, Crispens, MA, Jones, HW, Khabele, D, Gwin, K, Liang, SX, Mohammed, K, Desouki, MM, Parkash, V, Hecht, JL. Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. Am J Cancer Res, 3(1), 70-95, 2013

Fadare, O, Liang, SX, Crispens, MA, Jones, HW, Khabele, D, Gwin, K, Zheng, W, Mohammed, K, Parkash, V, Hecht, JL, Desouki, MM. Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. Hum Pathol, 2013

Fadare O. The molecular pathogenesis of endometrial clear-cell carcinoma: unclear, uncertain and possibly heterogeneous . Expert Review of Obstetrics & Gynecology, 7(2), 109-112, 2012

Fadare, O, Renshaw, IL, Liang, SX. Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot Assessment. J Cancer, 3, 129-36, 2012

Fadare, O, Liang, SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol, 20(6), 580-7, 2012

Fadare, O, Parkash, V, Dupont, WD, Acs, G, Atkins, KA, Irving, JA, Pirog, EC, Quade, BJ, Quddus, MR, Rabban, JT, Vang, R, Hecht, JL. The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features. Am J Surg Pathol, 36(8), 1107-18, 2012

Fadare, O, Zheng, W. Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach. Am J Cancer Res, 2(3), 335-9, 2012